Pediatric oncologist receives grant for neuroblastoma research
 Dr. Jason Shohet, a pediatric oncologist with Baylor College of Medicine and Texas Children's Cancer Center, has received a grant from Braden's Hope for Childhood Cancer, to support his research to find treatments for high-risk neuroblastoma, an aggressive cancer of young children. (Source: Baylor College of Medicine News)
Source: Baylor College of Medicine News - July 10, 2013 Category: Universities & Medical Training Source Type: news

Autophagy Protects Neuroblastoma From Chemotherapy
Neuroblastomas are pediatric tumors that originate from cells of the embryonic nervous system. The disease can take widely varying clinical courses that range from spontaneous regression to fatal outcomes. Highly aggressive neuroblastomas rarely respond well to chemotherapy. Understanding and overcoming the resistance mechanisms of highly aggressive neuroblastomas are considered essential to the development of effective treatments. Scientists from the department headed by Professor Dr... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 3, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Neuroblastoma: Autophagy protects from chemotherapy
(Helmholtz Association of German Research Centres) Cells can digest parts of themselves in a process called autophagy. This is a survival strategy that helps them overcome starvation and other conditions of depletion. In therapy-resistant cases of neuroblastoma, scientists from the German Cancer Research Center and Heidelberg University Hospital have now discovered an enzyme which promotes autophagy and thus protects cancer cells from treatment through chemotherapy. Blocking this enzyme might make cancer cells more sensitive to treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 1, 2013 Category: Global & Universal Source Type: news

First Stage Study Finds Potential New Drugs For Neuroblastoma
Scientists at The Institute of Cancer Research, London have made a step towards new, targeted drugs for children with the highestrisk form of a childhood cancer called neuroblastoma. In a preclinical study, published in journal Cancer Cell , researchers successfully used two potential drugs to target cancerous neuroblastoma cells with an overactive gene called MYCN. The gene plays a major role in most cases of aggressive and treatmentresistant neuroblastoma in children, as well as in some adult cancers... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 26, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Protocol for Flow Cytometric Sorting of Enriched Neuronal Cultures from iPSCs
Surface molecule profiles undergo dynamic changes in physiology and pathology, serve as markers of cellular state and phenotype and can be exploited for cell selection strategies and diagnostics. The isolation of well-defined cell subsets is needed for in vivo and in vitro applications in stem cell biology. In this technical report, the authors present an approach for defining a subset of interest in a mixed cell population by flow cytometric detection of intracellular antigens. They have developed a fully validated protocol that enables the co-detection of cluster of differentiation (CD) surface antigens on...
Source: Neuromics - June 25, 2013 Category: Neuroscience Tags: Stem Cell Research neuronal cultures induced pluripotent stem (iPS) cells CD Markers. Flow Cytometry cell sorting Neuronal Markers Neuronal Differentation nestin antibody human Source Type: news

Taking the fight to childhood cancer
Annabel Freyberg charts the advances and frustrations in the treatment of the tumour that claimed the life of her daughter, Blossom     (Source: Telegraph Health)
Source: Telegraph Health - June 24, 2013 Category: Consumer Health News Tags: children Blossom neuroblastoma Freyberg Annabel trials tumour cancer clinical Source Type: news

Girl, 15, who kept her terminal cancer a secret to lead a 'normal life' died just days after completing her GCSEs
Leah Wilby, from Great Yarmouth, beat neuroblastoma - a cancer of the nerve cells - when she was eight but it returned when she was 14. Her parents later learnt that she had achieved 10 A* to C grades in her GCSEs. (Source: the Mail online | Health)
Source: the Mail online | Health - June 20, 2013 Category: Consumer Health News Source Type: news

Phase 1 trial uses enhanced T cells to treat neuroblastoma
A phase 1 clinical trial at Baylor College of Medicine, which has received support from a pediatric cancer nonprofit organization, will use an immunotherapy approach to treating kids with neuroblastoma. (Source: Baylor College of Medicine News)
Source: Baylor College of Medicine News - June 10, 2013 Category: Universities & Medical Training Source Type: news

New Strategy For Defeating Neuroblastoma
Researchers at Karolinska Institutet in Sweden have found a promising strategy for defeating neuroblastoma - a malignant form of cancer in children - that focuses on the so-called MYCN protein. A specific chemical molecule helps to break down MYCN, which either kills the cancer cell or makes it mature into a harmless neuron. The discovery, which is published in the scientific journal PNAS, raises hopes for new and more effective treatments in the future. Neuroblastoma is the third most common form of cancer in children... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 5, 2013 Category: Consumer Health News Tags: Pediatrics / Children's Health Source Type: news

Hope Offered By New Treatment For Neuroblastoma
Researchers at Karolinska Institutet in Sweden have found a promising strategy for defeating neuroblastoma - a malignant form of cancer in children - that focuses on the so-called MYCN protein. A specific chemical molecule helps to break down MYCN, which either kills the cancer cell or makes it mature into a harmless neuron. The discovery, which is published in the scientific journal PNAS, raises hopes for new and more effective treatments in the future. Neuroblastoma is the third most common form of cancer in children... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 5, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Potential Alternative Drug Therapies For Neuroblastoma Revealed By New Genomic Screening
Nearly two-thirds of patients with high-risk neuroblastoma - a common tumor that forms in the nerve cells of children - cannot be cured using tumor-killing cancer drugs. A study published by Cell Press in the journal Chemistry & Biology reveals a new genomic approach to screen for compounds that could inhibit tumor growth by causing cancer cells to differentiate, or convert from immature cells to more specialized cell types... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 27, 2013 Category: Consumer Health News Tags: Neurology / Neuroscience Source Type: news

New screening approach uncovers potential alternative drug therapies for neuroblastoma
(Cell Press) Nearly two-thirds of patients with high-risk neuroblastoma -- a common tumor that forms in the nerve cells of children -- cannot be cured using tumor-killing cancer drugs. A study published in Chemistry & Biology reveals a new genomic approach to screen for compounds that inhibit tumor growth by causing cancer cells to differentiate. Using this screening method, the researchers identified a compound that causes neuroblastoma cells to differentiate, uncovering promising new treatment strategies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 23, 2013 Category: Cancer & Oncology Source Type: news

Treatment Switch For Neuroblastoma Stem Cell Transplants
The stem cell transplant regimen that was commonly used in the United States to treat advanced neuroblastoma in children appears to be more toxic than the equally effective regimen employed in Europe and Egypt, according to a new study being presented at the 26th annual meeting of the American Society of Pediatric Hematology Oncology in Miami April 24-27. The U.S. regimen was associated with more acute toxicity to the kidneys and liver... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 26, 2013 Category: Consumer Health News Tags: Neurology / Neuroscience Source Type: news

Neuroblastomas Vulnerable To Novel Class Of Drugs May Be Identified By Genetic Biomarker
An irregularity within many neuroblastoma cells may indicate whether a neuroblastoma tumor, a difficult-to-treat, early childhood cancer, is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors, Dana-Farber/Children's Hospital Cancer Center scientists reported at the annual meeting of the American Association for Cancer Research in Washington, April 6-10. The findings (abstract 4622) were discussed in a minisymposium. The work was published in Cancer Discovery, a journal of the American Association of Cancer Research... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 11, 2013 Category: Consumer Health News Tags: Neurology / Neuroscience Source Type: news

Pediatric cancer charities partner to fund international collaborative research
(Solving Kids' Cancer) Solving Kids' Cancer, along with UK-based charities Neuroblastoma Alliance UK, J-A-C-K, and other European organizations have aligned forces to improve access to promising clinical trials for children with high-risk neuroblastoma in North America, the UK and Europe. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 4, 2013 Category: Global & Universal Source Type: news

Neuroblastomas With Sensitivity To BET Bromodomain Inhibitors May Be Identified By Biomarker
Neuroblastoma, the most common malignant tumor of early childhood, is frequently associated with the presence of MYCN amplification, a genetic biomarker associated with poor prognosis. Researchers have determined that tumors containing MYCN amplification are sensitive to a new class of drugs, BET bromodomain inhibitors. The researchers made this discovery in a preclinical study, which was funded in part by a Stand Up To Cancer Innovative Research Grant and was published in Cancer Discovery, a journal of the American Association for Cancer Research... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 25, 2013 Category: Consumer Health News Tags: Neurology / Neuroscience Source Type: news

Biomarker may identify neuroblastomas with sensitivity to BET bromodomain inhibitors
(American Association for Cancer Research) The MYCN gene is commonly amplified in neuroblastoma and associated with poor prognosis. A BET bromodomain inhibitor downregulated MYCN expression. The drug prolonged survival in three animal models of MYCN-amplified neuroblastoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 21, 2013 Category: Global & Universal Source Type: news

Tumors of the Central Nervous System, Volume 9
Lymphoma, Supratentorial Tumors, Glioneuronal Tumors, Gangliogliomas, Neuroblastoma in Adults, Astrocytomas, Ependymomas, Hemangiomas, and Craniopharyngiomasseries:Tumors of the Central Nervous SystemThe ninth volume in this essential series discusses key advances in our understanding of neoplasms in the human central nervous system. This publication deals with various aspects of nine separate types of brain tumors. With 70 contributors from 17 nations, this edition offers an unrivalled thoroughness and breadth of coverage that includes the very latest research results on the following ... (Source: Springer Biomedical Sciences titles)
Source: Springer Biomedical Sciences titles - February 12, 2013 Category: Biomedical Science Tags: Biomedicine (general) Source Type: news

Complete Remission Induced By Dendritic Cell Vaccine For Relapsed Neuroblastoma Patient
One year after his last treatment, a six-year-old boy with recurrent neuroblastoma is in complete remission for his high-risk metastatic cancer. Doctors reported this case study in the January 2013 issue of Pediatrics, the journal of the American Academy of Pediatrics, which was funded in part by a joint grant from the Andrew McDonough B+ Foundation, Pierce Phillips Charity and Solving Kids' Cancer. Current treatments for high-risk neuroblastoma patients include chemotherapy, radiation therapy, surgery, stem cell transplant, and immunotherapy... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 31, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Surgery failed to improve survival in advanced neuroblastoma
Simon T. J Clin Oncol. 2013;doi:10.1200/JCO.2012.45.9339. (Source: HemOncToday.com)
Source: HemOncToday.com - January 30, 2013 Category: Cancer & Oncology Source Type: news

Dendritic cell vaccine for relapsed neuroblastoma patient induces complete remission
(Solving Kids' Cancer) One year after his last treatment, a six-year-old boy with recurrent neuroblastoma is in complete remission for his high-risk metastatic cancer. Doctors reported this case study in the Jan. 2013 issue of Pediatrics, the journal of the American Academy of Pediatrics. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 29, 2013 Category: Global & Universal Source Type: news

Researcher Leads Large Multicenter Gene Sequencing Study Of Neuroblastoma
An extensive genomic study of the childhood cancer neuroblastoma reinforces the challenges in treating the most aggressive forms of this disease. Contrary to expectations, the scientists found relatively few recurrent gene mutation - mutations that would suggest new targets for neuroblastoma treatment. Instead, say the researchers, they have now refocused on how neuroblastoma tumors evolve in response to medicine and other factors... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 22, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Tumors evolve rapidly in a childhood cancer, leaving fewer obvious treatment targets
An extensive genomic study of the childhood cancer neuroblastoma reinforces the challenges in treating the most aggressive forms of this disease. Unexpectedly, the scientists found relatively few recurrent gene mutations. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 20, 2013 Category: Science Source Type: news

Tumors evolve rapidly in a childhood cancer, leaving fewer obvious tumor targets
(Children's Hospital of Philadelphia) An extensive genomic study of the childhood cancer neuroblastoma reinforces the challenges in treating the most aggressive forms of this disease. Contrary to expectations, the scientists found relatively few recurrent gene mutations -- mutations that would suggest new targets for neuroblastoma treatment. Instead, say the researchers, they have now re-focused on how neuroblastoma tumors evolve in response to medicine and other factors. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 20, 2013 Category: Biology Source Type: news

Jamie Inglis, seven, of York, died from neuroblastoma in hospital in Tubingen, Germany
Jamie's mother Vicky Inglis, pictured here with him, said her son died peacefully in hospital in Germany after a long battle with the aggressive neuroblastoma. (Source: the Mail online | Health)
Source: the Mail online | Health - January 16, 2013 Category: Consumer Health News Source Type: news

Surgery not helpful in metastatic neuroblastoma
NEW YORK (Reuters Health) - Primary resection of stage 4 neuroblastoma does not appear to confer any benefit, German researchers say. (Source: Modern Medicine)
Source: Modern Medicine - January 2, 2013 Category: Journals (General) Source Type: news